Back to Search
Start Over
The long‐acting anti‐C5 ravulizumab results in C3 binding to PNH red cells similar to its parental molecule eculizumab.
- Source :
- British Journal of Haematology; Apr2023, Vol. 201 Issue 1, pe1-e4, 4p
- Publication Year :
- 2023
-
Abstract
- (A) C3d binding to PNH red cells in a PNH patient naïve to anti-C5 therapy who started ravulizumab. C3d binding to PNH red cells in a PNH patient naïve to anti-C5 therapy (left panel), during eculizumab treatment (middle panel) and after the switch to ravulizumab (right panel). [Extracted from the article]
Details
- Language :
- English
- ISSN :
- 00071048
- Volume :
- 201
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- British Journal of Haematology
- Publication Type :
- Academic Journal
- Accession number :
- 162730093
- Full Text :
- https://doi.org/10.1111/bjh.18662